Table 2.
Demographic and disease characteristics at the time of secukinumab initiation of patients with PsA (N = 153)
| Characteristic | Patients with PsA (N = 153) |
|---|---|
| Age, mean (SD), years | 47.3 (11.5) |
| Male, n (%) | 82 (53.6) |
| Race/ethnicity, n (%) | |
| White/non-Hispanic | 115 (75.2) |
| Hispanic | 19 (12.4) |
| Black/non-Hispanic | 10 (6.5) |
| Asian/Pacific Islander | 9 (5.9) |
| Insurance type, n (%) | |
| Commercial/private | 115 (75.2) |
| Medicare | 17 (11.1) |
| Medicaid | 17 (11.1) |
| Military | 5 (3.3) |
| Unknown/not sure | 3 (2.0) |
| Duration of PsA, n (%) | |
| < 1 year | 10 (6.5) |
| 1–2 years | 39 (25.5) |
| 3–5 years | 46 (30.1) |
| 6–10 years | 35 (22.9) |
| 11–15 years | 17 (11.1) |
| > 15 years | 6 (3.9) |
| Physician-assessed disease severity, n (%) | |
| Mild | 14 (9.2) |
| Moderate | 96 (62.7) |
| Severe | 43 (28.1) |
| PsA symptoms experienced, n (%)a | 150 (98.0) |
| Joint pain and swelling | 139 (90.8) |
| Stiffness | 134 (87.6) |
| Skin rashes | 113 (73.9) |
| Enthesitis | 71 (46.4) |
| Nail changes | 71 (46.4) |
| Fatigue | 70 (45.8) |
| Dactylitis | 57 (37.3) |
| Reduced range of motion | 56 (36.6) |
| Inflammatory eye disease | 6 (3.9) |
| Otherb | 3 (2.0) |
PsA psoriatic arthritis; SD standard deviation
aMultiple PsA symptoms could be selected for each patient except when “none of the above” was selected
bOther symptoms included “impaired activities of daily living and job performance (carpenter),” “could not hold eating utensils because of arthritis,” and “impaired activities of daily living (works as a chef).”